A preview of Intra-Cellular Therapies’ depression drug, and sizing up the MASH opportunity

I am one week away from the launch of my weekly email newsletter! It’s called Adam’s Biotech Scorecard, and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

Do you have a biotech-related question you want me to answer in the newsletter? Send me an email at [email protected].

This week: A preview of Intra-Cellular Therapies’ Phase 3 study in major depressive disorder, and a couple of liver-disease physician perspectives on Rezdiffra, the newly approved treatment for MASH from Madrigal Pharmaceuticals.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In